US00847G7051 - Common Stock - After market: 2.68 +0.12 (+4.69%)
NASDAQ:AGEN (12/6/2022, 7:20:22 PM)-0.23 (-8.24%)
|GICS Sector||Health Care|
|Earnings (Last)||11-08 2022-11-08/bmo||Earnings (Next)||02-27 2023-02-27|
|Ins Owners||0.46%||Inst Owners||53.83%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.
3 Forbes Rd
Lexington MASSACHUSETTS 02421
CEO: Garo H. Armen
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Agenus presented data this week on a combination therapy.
Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of...
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and...
Here you can normally see the latest stock twits on AGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.